化学
敌手
受体
体内
离体
效力
减肥
吲哚试验
药理学
肥胖
小分子
体重
体外
受体拮抗剂
药物发现
结构-活动关系
减肥
脚手架
对抗
铅化合物
内科学
临床研究阶段
不利影响
临床试验
内分泌学
相(物质)
衍生工具(金融)
G蛋白偶联受体
作者
Gyula Beke,András Mihály Boros,György Miklós Keserű,Balázs Krámos,Krisztina Szalai,Anikó Gere,Mónika Vastag,Márta Thán,Balázs Varga,Ottilia Balázs,Sándor Farkas,Balázs Lendvai,István Greiner,János Éles
标识
DOI:10.1021/acs.jmedchem.5c02708
摘要
High Resolution Image Download MS PowerPoint Slide The discovery and characterization of a novel 2,3,4,5-tetrahydro-1 H -[1,4]diazepino[1,7- a ]indole derivative MCH1 receptor antagonist ( 37 ) is disclosed. Starting from our previously investigated pyrazino[1,2- a ]indole series and utilizing a scaffold hopping strategy, pyrimidine- and 1,4-diazepine-fused indole derivatives were designed and synthesized. Among these, only the prototype molecule containing the 2,3,4,5-tetrahydro-1 H -[1,4]diazepino[1,7- a ]indole scaffold emerged as a chemically stable and potent MCHR1 antagonist. Previous SAR knowledge coupled with an ex vivo occupancy assay helped us to optimize this advanced lead to our candidate ( 37 ). The high MCHR1 potency and excellent receptor occupancy profile of 37 translated into statistically significant body weight loss after 14 days in a DIO mice study, supporting the potential use of this compound as a weight loss agent. Compound 37 (RGH-706) has successfully completed a phase I (SAD & MAD) clinical study in the indication of obesity, followed by an exploratory Phase II study in patients with Prader–Willi Syndrome (PWS).
科研通智能强力驱动
Strongly Powered by AbleSci AI